Octagon Capital Advisors LP Buys 543,000 Shares of Ocular Therapeutix, Inc. $OCUL

Octagon Capital Advisors LP boosted its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 20.7% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 3,166,600 shares of the biopharmaceutical company’s stock after buying an additional 543,000 shares during the period. Ocular Therapeutix accounts for approximately 3.0% of Octagon Capital Advisors LP’s holdings, making the stock its 15th largest position. Octagon Capital Advisors LP’s holdings in Ocular Therapeutix were worth $26,821,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of OCUL. Millennium Management LLC raised its stake in Ocular Therapeutix by 3,136.1% during the third quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock worth $45,073,000 after acquiring an additional 3,736,560 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Ocular Therapeutix by 2,003.2% during the third quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock valued at $40,032,000 after acquiring an additional 3,261,619 shares during the period. Vanguard Group Inc. boosted its stake in shares of Ocular Therapeutix by 26.3% in the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock valued at $140,523,000 after purchasing an additional 2,411,953 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Ocular Therapeutix by 106.5% in the 4th quarter. Janus Henderson Group PLC now owns 4,229,202 shares of the biopharmaceutical company’s stock valued at $51,321,000 after purchasing an additional 2,180,702 shares in the last quarter. Finally, Balyasny Asset Management L.P. grew its holdings in shares of Ocular Therapeutix by 902.9% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,189,276 shares of the biopharmaceutical company’s stock worth $25,593,000 after purchasing an additional 1,970,983 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on OCUL shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Friday, July 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, May 6th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price (up from $21.00) on shares of Ocular Therapeutix in a research note on Thursday, June 18th. Finally, Zacks Research cut shares of Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Twelve analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ocular Therapeutix currently has a consensus rating of “Moderate Buy” and an average price target of $25.11.

Insider Buying and Selling at Ocular Therapeutix

In related news, insider Pravin Dugel sold 21,156 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total value of $173,479.20. Following the completion of the transaction, the insider owned 2,597,170 shares in the company, valued at $21,296,794. The trade was a 0.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 28,999 shares of company stock valued at $237,792 over the last three months. Company insiders own 3.10% of the company’s stock.

Ocular Therapeutix Stock Performance

Shares of NASDAQ OCUL opened at $8.51 on Monday. Ocular Therapeutix, Inc. has a 1-year low of $6.23 and a 1-year high of $16.44. The company has a 50-day moving average of $9.12 and a two-hundred day moving average of $9.28. The company has a market cap of $1.86 billion, a PE ratio of -5.83 and a beta of 0.88. The company has a current ratio of 14.81, a quick ratio of 14.73 and a debt-to-equity ratio of 0.12.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.